Rosiglitazone, but Not Pioglitazone, Improves Myocardial Systolic Function in Type 2 Diabetic Patients: A Tissue Doppler Study
- 25 May 2010
- journal article
- research article
- Published by Wiley in Echocardiography
- Vol. 27 (5), 512-518
- https://doi.org/10.1111/j.1540-8175.2009.01083.x
Abstract
Despite many potential benefits, thiazolidinedione (TZD) use has been associated with increased exacerbation rate of heart failure due to fluid retention. In our study, the effect of rosiglitazone and pioglitazone on myocardial function in patients with type 2 diabetes mellitus (DM) and normal left ventricular systolic function was evaluated by both conventional echocardiography and tissue Doppler imaging (TDI). Forty patients who were diagnosed type 2 DM according to the American Diabetes Association criteria were included in the study. After baseline evaluation, all patients were randomly assigned to receive either rosiglitazone 4 mg twice daily or pioglitazone 30 mg daily for 4 months. Blood samples were taken and detailed pulsed-wave and tissue Doppler echocardiographic examination was performed at baseline and 4 months after TZD therapy. Left ventricular systolic velocity (Sm) values were found to be significantly increased in the rosiglitazone group (+2.6 + or - 0.7 cm/sec, P < 0.0001), while they remained unchanged in the pioglitazone group. Left ventricular early diastolic velocity (Em) increased at the same extent in both groups after treatment (rosioglitazone: +0.7 + or - 0.7 cm/sec; pioglitazone: +0.5 + or - 0.4 cm/sec, P < 0.05). In conclusion, while rosiglitazone and pioglitazone therapy improved metabolic parameters, blood pressure values and diastolic function similarly, in type 2 diabetic patients, only rosiglitazone improved systolic myocardial function significantly. (Echocardiography 2010;27:512-518).Keywords
This publication has 23 references indexed in Scilit:
- Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe ObesityClinical Cardiology, 2008
- Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitusActa Diabetologica, 2007
- A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart FailureJournal of the American College of Cardiology, 2007
- PPAR-γ agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureCirculation, 2003
- Glitazones: clinical effects and molecular mechanismsAnnals of Medicine, 2002
- Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In VivoCirculation, 2002
- Glitazones: clinical effects and molecular mechanismsAnnals of Medicine, 2002
- Ca2+‐sensitizing effect is involved in the positive inotropic effect of troglitazoneBritish Journal of Pharmacology, 2001
- Peroxisome proliferator‐activated receptors in the cardiovascular systemBritish Journal of Pharmacology, 2000